Sign In
Buy LIXT
$7.30
-0.180 (-2.41%)
At Close: Jun 23, 2026
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:42am, Tuesday, 11'th Feb 2025
PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today annou
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
05:00pm, Monday, 10'th Feb 2025
PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today ann
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
08:30am, Wednesday, 04'th Sep 2024
Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a
LIXTE Biotechnology Provides Update On Recent Activities and Developments
08:30am, Monday, 19'th Aug 2024
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company-
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
08:30am, Thursday, 15'th Aug 2024
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26 th Annual Global Investment Conference-
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
10:50pm, Wednesday, 14'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and develop
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
11:00am, Friday, 14'th Jun 2024
Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
09:30am, Friday, 14'th Jun 2024
Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
08:30am, Monday, 03'rd Jun 2024
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing
LIXTE Biotechnology Holdings Provides Update on Recent Activities
08:30am, Monday, 20'th May 2024
PASADENA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
09:25am, Wednesday, 08'th May 2024
Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard's Dana Farber Cancer Institute in Boston
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
08:30am, Thursday, 21'st Mar 2024
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or th
Conference In Dublin, Ireland on February 27 - 29, 2024 Focuses on How to Bring Basic Science Discoveries to the Clinic
